Study of Early Pharmaceutical Intervention for Cardiovascular Disease Prevention in Stage 1 Hypertension
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
STEP-Pre is to investigate the benefits of using anti-hypertensive drugs in the population
with a blood pressure of 130-139/80-89 mmHg and evaluate the health economics.
STEP-Pre is a multi-center randomized clinical trial. The cohort will be randomized into the
treatment group or control group with a 1:1 ratio. The treatment group will take
anti-hypertensive medicine to control blood pressure under 130/80 mmHg. Both groups will take
health care education.
STEP-Pre will last 4 years.
Phase:
N/A
Details
Lead Sponsor:
Chinese Academy of Medical Sciences, Fuwai Hospital